{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:16:29Z","timestamp":1788542189518,"version":"build-2803163510"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Managing rare diseases presents substantial challenges to achieving universal health coverage. Despite growing policy interest, limited research has explored the evolution and synergy of healthcare security policies targeting rare diseases. This study addresses this gap through a case study of China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An innovative analytical framework was developed, structured around three dimensions of policy synergy: horizontal, vertical, and temporal. A comprehensive dataset of national and provincial policy documents related to healthcare security for rare diseases was systematically collected. Analytical techniques included quantitative content analysis, word frequency analysis, and semantic network analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 314 policies enacted between 2001 and 2025 remained effective at the time of data collection, showing a general upward trend in both quantity and policy strength. However, the majority of policies were notices and announcements, which typically carry lower enforcement authority than ordinances and regulations. While a diverse array of policy instruments was employed, horizontal synergy across sectors remained limited. Vertically, national policies emphasized screening and support for children with rare diseases, whereas provincial policies focused more on outpatient service subsidies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rare diseases have gained increasing attention within China\u2019s healthcare security policy landscape. Nonetheless, significant gaps in horizontal and vertical policy synergy persist. A systems-based approach is recommended to enhance policy integration and effectiveness.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1864284","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:34:00Z","timestamp":1784612040000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Evolution and synergy of healthcare security policies for rare diseases in China: a quantitative content analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Jingying","family":"Gao","sequence":"first","affiliation":[{"name":"School of Medicine and Health Management, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaojie","family":"Liu","sequence":"additional","affiliation":[{"name":"School of Psychology and Public Health, La Trobe University","place":["Melbourne, VIC, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine and Health Management, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojia","family":"Cai","sequence":"additional","affiliation":[{"name":"School of Medicine and Health Management, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Tang","sequence":"additional","affiliation":[{"name":"School of Medicine and Health Management, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, Hubei, China"]},{"name":"Major Disciplinary Platform under Double First-Class Initiative for Liberal Arts at Huazhong University of Science and Technology (Research Center for High-Quality Development of Hospitals)","place":["Wuhan, Hubei, China"]},{"name":"Key Research Institute of Humanities and Social Sciences of Hubei Provincial Department of Education","place":["Wuhan, Hubei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"914338","DOI":"10.3389\/fphar.2022.914338","article-title":"Valuing the \u201cburden\u201d and impact of rare diseases: a scoping review","volume":"13","author":"Delaye","year":"2022","journal-title":"Front Pharmacol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/S2214-109X(24)00056-1","article-title":"The landscape for rare diseases in 2024","volume":"12","year":"2024","journal-title":"Lancet Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/s41431-019-0508-0","article-title":"Estimating cumulative point prevalence of rare diseases: analysis of the orphanet database","volume":"28","author":"Nguengang Wakap","year":"2020","journal-title":"Eur J Hum Genet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/j.healthpol.2014.12.016","article-title":"Socio-economic burden of rare diseases: a systematic review of cost of illness evidence","volume":"119","author":"Angelis","year":"2015","journal-title":"Health Policy"},{"key":"ref5","year":"2022"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13023-024-03099-9","article-title":"Cost-of-illness studies of inherited retinal diseases: a systematic review","volume":"19","author":"Ng","year":"2024","journal-title":"Orphanet J Rare Dis"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.3389\/fphar.2019.00487","article-title":"Reimbursement legislations and decision making for orphan drugs in central and eastern European countries","volume":"10","author":"Malinowski","year":"2019","journal-title":"Front Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1186\/s13023-020-01462-0","article-title":"Are supplemental appraisal\/reimbursement processes needed for rare disease treatments? An international comparison of country approaches","volume":"15","author":"Nicod","year":"2020","journal-title":"Orphanet J Rare Dis"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13561-024-00519-1","article-title":"Comparative policy analysis of national rare disease funding policies in Australia, Singapore, South Korea, the United Kingdom and the United States: a scoping review","volume":"14","author":"Ng","year":"2024","journal-title":"Heal Econ Rev"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1016\/j.jval.2024.07.005","article-title":"The health benefits, costs, and cost-effectiveness of ultraorphan drugs","volume":"27","author":"Clifford","year":"2024","journal-title":"Value Health"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"A567","DOI":"10.1016\/j.jval.2017.08.959","article-title":"Access to medicines for rare diseases in Australia: the current climate for reimbursement","volume":"20","author":"Lee","year":"2017","journal-title":"Value Health"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"A14","DOI":"10.1016\/j.jval.2012.03.087","article-title":"PHP10 Australia\u2019s rule of rescue and the life saving drugs programme: same-same but different?","volume":"15","author":"Priest","year":"2012","journal-title":"Value Health"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1001\/jama.2022.15268","article-title":"New reforms to prescription drug pricing in the US: opportunities and challenges","volume":"328","author":"Hwang","year":"2022","journal-title":"JAMA"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jamainternmed.2023.6293","article-title":"Cost of exempting sole orphan drugs from Medicare negotiation","volume":"184","author":"Vogel","year":"2024","journal-title":"JAMA Intern Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21678707.2024.2313766","article-title":"Orphan drugs approved in Canada: health technology assessment, price negotiation, and government formulary listing","volume":"12","author":"Rawson","year":"2024","journal-title":"Expert Opin Orphan Drugs"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1016\/j.jval.2022.09.1180","article-title":"HPR48 reimbursement policies regarding rare diseases in central and eastern European countries","volume":"25","author":"Sk\u00f3ra","year":"2022","journal-title":"Value Health"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1369817","DOI":"10.1080\/20016689.2017.1369817","article-title":"The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change","volume":"5","author":"Young","year":"2017","journal-title":"J Mark Access Health Policy"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.healthpol.2018.04.009","article-title":"Access to orphan drugs\u2014comparison across Balkan countries","volume":"122","author":"Pejcic","year":"2018","journal-title":"Health Policy"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1079601","DOI":"10.3389\/fpubh.2023.1079601","article-title":"Undiagnosed diseases: needs and opportunities in 20 countries participating in the undiagnosed diseases network international","volume":"11","author":"Taruscio","year":"2023","journal-title":"Front Public Health"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13023-025-03634-2","article-title":"Debates over orphan drug pricing: a meta-narrative literature review","volume":"20","author":"Hanchard","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1111\/j.1540-6210.2007.00797.x","article-title":"The whole-of-government approach to public sector reform","volume":"67","author":"Christensen","year":"2007","journal-title":"Public Adm Rev"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.drugpo.2012.08.004","article-title":"Drug policy coordination: identifying and assessing dimensions of coordination","volume":"24","author":"Hughes","year":"2013","journal-title":"Int J Drug Policy"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/hpm.3712","article-title":"Rare diseases in developing countries: insights from China\u2019s collaborative network","volume":"39","author":"Chen","year":"2024","journal-title":"Int J Health Plann Manag"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"509842","DOI":"10.3389\/fpubh.2020.509842","article-title":"Text mining and quantitative research of medical service policy: Sichuan province as an example","volume":"8","author":"Zhang","year":"2020","journal-title":"Front Public Health"},{"key":"ref25","year":"2000"},{"key":"ref26","first-page":"45","article-title":"The regional environmental governance from the perspective of the intergovernmental relations: a quantitative analysis of the air pollution prevent policy texts in the Beijing-Tianjin-Hebei region","volume":"24","author":"Sun","year":"2017","journal-title":"Urban Dev Stud"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"e0240515","DOI":"10.1371\/journal.pone.0240515","article-title":"Synergy effect of science and technology policies on innovation: evidence from China","volume":"15","author":"Pang","year":"2020","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"107104","DOI":"10.1016\/j.eneco.2023.107104","article-title":"Which combinations of renewable energy policies work better? Insights from policy text synergies in China","volume":"127","author":"Hu","year":"2023","journal-title":"Energy Econ"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"123581","DOI":"10.1016\/j.jenvman.2024.123581","article-title":"Synergistic effects of air pollution control policies: evidence from China","volume":"373","author":"Feng","year":"2025","journal-title":"J Environ Manag"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"123389","DOI":"10.1016\/j.jenvman.2024.123389","article-title":"Policy synergy analysis on coordinating reduction of pollution and carbon emissions in China: insights from text mining and network analysis","volume":"372","author":"Zhu","year":"2024","journal-title":"J Environ Manag"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"73","DOI":"10.5582\/irdr.2024.01001","article-title":"Epidemiology and distribution of 207 rare diseases in China: a systematic literature review","volume":"13","author":"Wang","year":"2024","journal-title":"Intractable Rare Dis Res."},{"key":"ref32","year":"2024"},{"key":"ref33","author":"Wang","year":"2022"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"80","DOI":"10.5582\/irdr.2019.01068","article-title":"Accessibility of drugs for rare diseases in China: policies and current situation","volume":"8","author":"Yang","year":"2019","journal-title":"Intractable Rare Dis Res."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"148","DOI":"10.5582\/irdr.2021.01027","article-title":"An update on China\u2019s national policies regarding rare diseases","volume":"10","author":"Ying","year":"2021","journal-title":"Intractable Rare Dis Res"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1180550","DOI":"10.3389\/fmed.2023.1180550","article-title":"Policy analysis in the field of rare diseases in China: a combined study of content analysis and bibliometrics analysis","volume":"10","author":"Li","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"101770","DOI":"10.1016\/j.techsoc.2021.101770","article-title":"Evaluation of China\u2019s new energy vehicle policy texts with quantitative and qualitative analysis","volume":"67","author":"Wang","year":"2021","journal-title":"Technol Soc"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"102547","DOI":"10.1016\/j.resourpol.2021.102547","article-title":"Evaluation of the synergy degree of industrial de-capacity policies based on text mining: a case study of China\u2019s coal industry","volume":"76","author":"Liu","year":"2022","journal-title":"Resour Policy"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.16868\/j.cnki.1674-6252.2021.03.092","article-title":"Evolution, coordination and textual content analysis of China\u2019s green service policy","volume":"13","author":"Dan","year":"2021","journal-title":"Chin J Environ Manage"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"114585","DOI":"10.1016\/j.rser.2024.114585","article-title":"Quantifying the synergy of China\u2019s carbon neutrality policies through policy documents","volume":"200","author":"Chen","year":"2024","journal-title":"Renew Sust Energ Rev"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1131590","DOI":"10.3389\/fmars.2023.1131590","article-title":"Evaluation of policy synergy in coastal ocean pollution prevention and control: the case from China","volume":"10","author":"Yao","year":"2023","journal-title":"Front Mar Sci"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"5551","DOI":"10.1007\/s10668-024-05190-4","article-title":"Can China\u2019s energy policies achieve the \u201cdual carbon\u201d goal? A multi-dimensional analysis based on policy text tools","volume":"28","author":"Zhu","year":"2024","journal-title":"Environ Dev Sustain"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"122931","DOI":"10.1016\/j.techfore.2023.122931","article-title":"Policy modeling consistency analysis during energy crises: evidence from China\u2019s coal power policy","volume":"197","author":"Zhang","year":"2023","journal-title":"Technol Forecast Soc Change"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"122770","DOI":"10.1016\/j.techfore.2023.122770","article-title":"Is the photovoltaic power generation policy effective in China? A quantitative analysis of policy synergy based on text mining","volume":"195","author":"Chong","year":"2023","journal-title":"Technol Forecast Soc Change"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"105293","DOI":"10.1016\/j.ocecoaman.2020.105293","article-title":"Evolution of marine spatial planning policies for mariculture in China: overview, experience and prospects","volume":"196","author":"Yu","year":"2020","journal-title":"Ocean Coast Manag"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.3390\/su11185076","article-title":"Evolution of marine environmental governance policy in China","volume":"11","author":"Yu","year":"2019","journal-title":"Sustainability"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/0038038588022001007","article-title":"Social network analysis","volume":"22","author":"Scott","year":"1988","journal-title":"Sociology"},{"key":"ref48","volume-title":"NetDraw: Graph Visualization Software","author":"Borgatti","year":"2002"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"126","DOI":"10.5582\/ddt.2013.v7.3.126","article-title":"Rare disease patients in China anticipate the sunlight of legislation","volume":"7","author":"Gao","year":"2013","journal-title":"Drug Discov Ther"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jval.2024.12.009","article-title":"Rare disease policy in high-income countries: an overview of achievements, challenges, and solutions","volume":"28","author":"Gentilini","year":"2025","journal-title":"Value Health"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10545-016-9995-0","article-title":"Household financial burden of phenylketonuria and its impact on treatment in China: a cross-sectional study","volume":"40","author":"Wang","year":"2017","journal-title":"J Inherit Metab Dis"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e064811","DOI":"10.1136\/bmjopen-2022-064811","article-title":"Impacts of adjustment of national reimbursement drug list on orphan drugs volume and spending in China: an interrupted time series analysis","volume":"13","author":"Yi","year":"2023","journal-title":"BMJ Open"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.vhri.2022.10.008","article-title":"Patient access to orphan drugs covered by medical insurance in China: real-world evidence from patient survey","volume":"34","author":"Wang","year":"2023","journal-title":"Value Health Reg Issues"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12962-022-00409-5","article-title":"Understanding the impact of unequal utilization of medical services on the consumption of resources in hemophilia","volume":"20","author":"Li","year":"2022","journal-title":"Cost Eff Resour Alloc"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3389\/fphar.2018.01263","article-title":"Reimbursement of orphan drugs in Europe in relation to the type of authorization by the European medicines agency and the decision making based on health technology assessment","volume":"9","author":"Malinowski","year":"2018","journal-title":"Front Pharmacol"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00228-018-2457-x","article-title":"Policies and availability of orphan medicines in outpatient care in 24 European countries","volume":"74","author":"Sarnola","year":"2018","journal-title":"Eur J Clin Pharmacol"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/j.1365-2710.2012.01364.x","article-title":"Market uptake of orphan drugs\u2014a European analysis","volume":"37","author":"Picavet","year":"2012","journal-title":"J Clin Pharm Ther"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13023-016-0455-6","article-title":"Systematic review on the evaluation criteria of orphan medicines in central and eastern European countries","volume":"11","author":"Zelei","year":"2016","journal-title":"Orphanet J Rare Dis"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3389\/fpubh.2019.00416","article-title":"A review of rare disease policies and orphan drug reimbursement systems in 12 Eurasian countries","volume":"7","author":"Czech","year":"2019","journal-title":"Front Public Health"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12939-025-02388-4","article-title":"Rare disease challenges and potential actions in the Middle East","volume":"24","author":"Fasseeh","year":"2025","journal-title":"Int J Equity Health"},{"key":"ref61","year":"2019"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1864284\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:34:03Z","timestamp":1784612043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1864284\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":61,"alternative-id":["10.3389\/fpubh.2026.1864284"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1864284","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1864284"}}